State Street Corp Syros Pharmaceuticals, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $639,996 - $1.12 Million	-927,531 Reduced 81.41%	211,820 $204,000
Q1 2022 May 16, 2022	SELL	$1.02 - $3.8 $9,779 - $36,434	-9,588 Reduced 0.83%	1,139,351 $1.36 Million
Q4 2021 Feb 14, 2022	BUY	$3.26 - $4.66 $108,776 - $155,490	33,367 Added 2.99%	1,148,939 $3.75 Million
Q3 2021 Nov 15, 2021	BUY	$4.08 - $5.66 $474,577 - $658,359	116,318 Added 11.64%	1,115,572 $4.99 Million
Q2 2021 Aug 16, 2021	BUY	$5.01 - $7.48 $1.02 Million - $1.53 Million	203,909 Added 25.64%	999,254 $5.45 Million
Q1 2021 May 17, 2021	BUY	$7.19 - $14.95 $491,839 - $1.02 Million	68,406 Added 9.41%	795,345 $5.95 Million
Q4 2020 Feb 16, 2021	SELL	$6.66 - $14.66 $6.48 Million - $14.3 Million	-972,543 Reduced 57.23%	726,939 $7.89 Million
Q3 2020 Nov 10, 2020	BUY	$8.69 - $14.47 $7.42 Million - $12.4 Million	854,333 Added 101.09%	1,699,482 $15 Million
Q2 2020 Aug 14, 2020	BUY	$5.21 - $11.03 $1 Million - $2.12 Million	192,018 Added 29.4%	845,149 $9.01 Million
Q1 2020 May 11, 2020	BUY	$4.46 - $9.2 $2.91 Million - $6.01 Million	653,131 New	653,131 $3.87 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $4.86M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.